February 15, 2018 / 12:10 PM / 3 days ago

BRIEF-Shire Announces FDA Acceptance Of sBLA For Cinryze For Pediatric Hereditary Angioedema Use

Feb 15 (Reuters) - Shire Plc:

* SHIRE ANNOUNCES FDA ACCEPTANCE OF SBLA FOR CINRYZE® FOR PEDIATRIC HEREDITARY ANGIOEDEMA USE

* SHIRE PLC - FILING HAS RECEIVED PRIORITY REVIEW DESIGNATION FROM FDA

* SHIRE PLC - FDA EXPECTED TO PROVIDE DECISION ON EXPANDED INDICATION OF CINRYZE BY JUNE 20, 2018, BASED ON PDUFA V ACTION DAT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below